Apolipoprotein B and interleukin 1 receptor antagonist: reversing the risk of coronary heart disease.
apolipoprotein B
coronary heart disease
interleukin 1 receptor antagonist
lifestyle modification
myocardial infarction
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
08
2023
accepted:
05
10
2023
medline:
10
11
2023
pubmed:
9
11
2023
entrez:
9
11
2023
Statut:
epublish
Résumé
Epidemiological evidence for the link of interleukin 1 (IL-1) and its inhibition with cardiovascular diseases (CVDs) remains controversial. We aim to investigate the cardiovascular effects of IL-1 receptor antagonist (IL-1Ra) and underlying mechanisms. Genetic variants identified from a genome-wide association study involving 30,931 individuals were used as instrumental variables for the serum IL-1Ra concentrations. Genetic associations with CVDs and cardiometabolic risk factors were obtained from international genetic consortia. Inverse-variance weighted method was utilized to derive effect estimates, while supplementary analyses employing various statistical approaches. Genetically determined IL-1Ra level was associated with increased risk of coronary heart disease (CHD; OR, 1.07; 95% CI: 1.03-1.17) and myocardial infarction (OR, 1.13; 95% CI: 1.04-1.21). The main results remained consistent in supplementary analyses. Besides, IL-1Ra was associated with circulating levels of various lipoprotein lipids, apolipoproteins and fasting glucose. Interestingly, observed association pattern with CHD was reversed when adjusting for apolipoprotein B (OR, 0.84; 95%CI: 0.71-0.99) and slightly attenuated on accounting for other cardiometabolic risk factors. Appropriate lifestyle intervention was found to lower IL-1Ra concentration and mitigate the heightened CHD risk it posed. Apolipoprotein B represents the key driver, and a potential target for reversal of the causal link between serum IL-1Ra and increased risk of CHD/MI. The combined therapy involving IL-1 inhibition and lipid-modifying treatment aimed at apolipoprotein B merit further exploration.
Identifiants
pubmed: 37941911
doi: 10.3389/fendo.2023.1278273
pmc: PMC10628700
doi:
Substances chimiques
Interleukin 1 Receptor Antagonist Protein
0
Apolipoproteins B
0
Apolipoproteins
0
Interleukin-1
0
Receptors, Interleukin-1
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1278273Informations de copyright
Copyright © 2023 Yang, Huangfu, Shen, Su, Zhu, Cui and Yuan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Natl Cancer Inst. 2014 Oct 01;106(11):
pubmed: 25274579
Nat Methods. 2012 Apr 27;9(5):459-62
pubmed: 22543379
Psychol Med. 2020 Oct;50(14):2435-2443
pubmed: 31689377
J Clin Invest. 2012 Jan;122(1):70-9
pubmed: 22201681
Nat Genet. 2019 Mar;51(3):394-403
pubmed: 30804565
Nature. 2014 Feb 20;506(7488):376-81
pubmed: 24390342
Int J Obes (Lond). 2018 Jun;42(6):1161-1176
pubmed: 29899525
J Sport Health Sci. 2019 May;8(3):201-217
pubmed: 31193280
Nat Commun. 2020 Jan 9;11(1):163
pubmed: 31919418
Front Cell Infect Microbiol. 2022 Mar 22;12:853096
pubmed: 35392608
J Am Soc Nephrol. 2016 Nov;27(11):3253-3265
pubmed: 27486138
Genet Epidemiol. 2013 Nov;37(7):658-65
pubmed: 24114802
Circ Cardiovasc Imaging. 2014 Jul;7(4):619-28
pubmed: 24782115
Hum Mol Genet. 2016 Dec 15;25(24):5472-5482
pubmed: 27702941
Genet Epidemiol. 2016 May;40(4):304-14
pubmed: 27061298
Nat Commun. 2019 Mar 7;10(1):1100
pubmed: 30846698
Nature. 2015 Feb 12;518(7538):187-196
pubmed: 25673412
Pharmacol Res. 2018 May;131:44-50
pubmed: 29588192
Nat Med. 2018 Sep;24(9):1418-1429
pubmed: 30038218
Int J Epidemiol. 2015 Apr;44(2):484-95
pubmed: 25150977
Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1222-1227
pubmed: 28428221
Nat Neurosci. 2018 Dec;21(12):1656-1669
pubmed: 30482948
Elife. 2018 May 30;7:
pubmed: 29846171
Lancet Diabetes Endocrinol. 2015 Apr;3(4):228-9
pubmed: 25726325
Immunity. 2019 Apr 16;50(4):778-795
pubmed: 30995499
Int J Cardiol. 2020 Aug 15;313:99-104
pubmed: 32223966
Nat Genet. 2018 Sep;50(9):1234-1239
pubmed: 30061737
Am J Epidemiol. 2015 Feb 15;181(4):251-60
pubmed: 25632051
J Am Coll Cardiol. 2022 Mar 1;79(8):837-847
pubmed: 35210039
Circ Res. 2020 Apr 24;126(9):1260-1280
pubmed: 32324502
Eur Heart J. 2015 Feb 7;36(6):377-84
pubmed: 25079365
Am J Hum Genet. 2018 Nov 1;103(5):691-706
pubmed: 30388399
Int J Epidemiol. 2015 Apr;44(2):512-25
pubmed: 26050253
Nat Metab. 2020 Oct;2(10):1135-1148
pubmed: 33067605
Nat Genet. 2018 May;50(5):693-698
pubmed: 29686387
Hum Mol Genet. 2019 Jul 15;28(14):2449-2457
pubmed: 31046077
PLoS Med. 2020 Mar 23;17(3):e1003062
pubmed: 32203549
Int J Epidemiol. 2017 Dec 1;46(6):1734-1739
pubmed: 28398548
JAMA Cardiol. 2019 Dec 1;4(12):1287-1295
pubmed: 31642874
Nat Genet. 2015 Oct;47(10):1121-1130
pubmed: 26343387
Nat Commun. 2020 Apr 21;11(1):1770
pubmed: 32317632
Arterioscler Thromb Vasc Biol. 2014 Dec;34(12):2695-9
pubmed: 25341801
Lancet Diabetes Endocrinol. 2015 Apr;3(4):243-53
pubmed: 25726324
Nat Genet. 2021 Jun;53(6):840-860
pubmed: 34059833
Sci Rep. 2022 Aug 11;12(1):13698
pubmed: 35953706
Wellcome Open Res. 2019 Nov 26;4:186
pubmed: 32760811
J Clin Med. 2023 Feb 06;12(4):
pubmed: 36835838
Trends Cardiovasc Med. 2022 May;32(4):181-194
pubmed: 33872757
Nat Genet. 2018 Oct;50(10):1412-1425
pubmed: 30224653
Hum Mol Genet. 2019 Jan 1;28(1):166-174
pubmed: 30239722
Nat Genet. 2018 Apr;50(4):524-537
pubmed: 29531354
Nat Genet. 2019 Feb;51(2):237-244
pubmed: 30643251